Reference | 1. Dr Maria Corinna A Palanca-Wessels, Prof Myron Czuczman, Prof Gilles Salles, Sarit Assouline, Laurie H Sehn, Ian Flinn, et al; Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. ARTICLES| VOLUME 16, ISSUE 6, P704-715, JUNE 2015.
. |